HPV testing in the context of post-treatment follow up (test of cure)

Journal of Clinical Virology

Volumn 76, Issue , 2016, Pages S56-S61

  Cuschieri, Kate ^a   Bhatia, Ramya ^b   Cruickshank, Margaret ^c   Hillemanns, Peter ^d   Arbyn, Marc ^e  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ABERDEEN MATERNITY HOSPITAL   (United Kingdom)

^d LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^e SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Cervical lesions; Human papillomavirus; Post treatment; Test of cure; Testing strategies

Indexed keywords

CYTOLOGY; FOLLOW UP; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SENSITIVITY AND SPECIFICITY; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; COMPLICATION; FEMALE; GENETICS; GENOTYPING TECHNIQUE; ISOLATION AND PURIFICATION; MASS SCREENING; METABOLISM; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

PHARMACOLOGICAL BIOMARKER; VIRUS DNA;

BIOMARKERS, PHARMACOLOGICAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPING TECHNIQUES; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 84960096730     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.10.008     Document Type: Review

References (55)

1. http://www.who.int/cancer/detection/cervical_cancer_screening/en/.
2. Jordan J., Martin-Hirsch P., Arbyn M., Schenck U., Baldauf J.J., Da Silva D., Anttila A., Nieminen P., Prendiville W. European guidelines for clinical management of abnormal cervical cytology, part 2. Cytopathology 2009, 20:5-16.
3. Strander B., Andersson-Ellström A., Milsom I., Sparén P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ 2007, 335(7629):1077.
4. Mitchell H., Medley G., Carlin J.B. Risk of subsequent cytological abnormality and cancer among women with a history of cervical intraepithelial neoplasia: a comparative study. Cancer Causes Control 1990, 1:143-148.
5. Pettersson F., Malker B. Invasive carcinoma of the uterine cervix following diagnosis and treatment of in situ carcinoma. Record linkage study within a national cancer registry. Radiother. Oncol. 1989, 16:115-120.
6. Rapiti E., Usel M., Neyroud-Caspar I., Merglen A., Verkooijen H.M., Vlastos A.T., Pache J.C., Kumar N., Bouchardy C. Omission of excisional therapy is associated with an increased risk of invasive cervical cancer after cervical intraepithelial neoplasia III. Eur. J. Cancer 2012, 48:845-852.
7. Ghaem-Maghami S., Sagi S., Majeed G., Soutter W.P. Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis. Lancet Oncol. 2007, 8:985-993.
8. Soutter W.P., Sasieni P., Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int. J. Cancer 2006, 118:2048-2055.
9. Strander B., Hällgren J., Sparén P. Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. BMJ 2014, 348:f7361. 10.1136/bmj.f7361.
10. Rebolj M., Helmerhorst T., Habbema D., Looman C., Boer R., van Rosmalen J., van Ballegooijen M. Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study. BMJ 2012, 345:e6855. 10.1136/bmj.e6855.
11. Mohanty G., Ghosh S.N. Risk factors for cancer of cervix, status of screening and methods for its detection. Arch. Gynecol. Obstet. 2015, 201(291):247-249.
12. Schiffman M., Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol. Biomarkers Prev. 2013, 22:553-560.
13. Dugué P.A., Rebolj M., Garred P., Lynge E. Immunosuppression and risk of cervical cancer. Expert Rev. Anticancer Ther. 2013, 13:29-42.
14. Martin-Hirsch P.L., Paraskevaidis E., Kitchener H. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst. Rev. 2000, 2:CD001318. Review. Update in: Cochrane Database Syst Rev. 2010; CD001318.
15. Ghaem-Maghami S., De-Silva D., Tipples M., Lam S., Perryman K., Soutter W. Determinants of success in treating cervical intraepithelial neoplasia. BJOG 2015, 118:679-684.
16. Paraskevaidis E., Arbyn M., Sotiriadis A., Diakomanolis E., Martin-Hirsch P., Koliopoulos G., Makrydimas G., Tofoski J., Roukos D.H. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat. Rev. 2004, 30:205-211.
17. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006, 24(Suppl. (3)):S78-S89.
18. Kocken M., Uijterwaal M.H., de Vries A.L., Berkhof J., Ket J.C., Helmerhorst T.J., Meijer C.J. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol. Oncol. 2012, 125:500-507.
19. Arbyn M., Ronco G., Anttila A., Meijer C.J., Poljak M., Ogilvie G., Koliopoulos G., Naucler P., Sankaranarayanan R., Peto J. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012, 30(Suppl. (5)):F88-F99.
20. Massad L.S., Einstein M.H., Huh W.K., Katki H.A., Kinney W.K., Schiffman M., Solomon D., Wentzensen N., Lawson H.W. ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J. Low Genit. Tract. Dis. 2013, 17(Suppl. 1 (5)):S1-27. Erratum in: J. Low. Genit. Tract Dis. 2013, 17, 367.
21. Kocken M., Helmerhorst T.J., Berkhof J., Louwers J.A., Nobbenhuis M.A., Bais A.G., Hogewoning C.J., Zaal A., Verheijen R.H., Snijders P.J., Meijer C.J. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol. 2011, 12:441-450.
22. Uijterwaal M.H., Kocken M., Berkhof J., Bekkers R.L., Verheijen R.H., Helmerhorst T.J., Meijer C.J. Posttreatment assessment of women at risk of developing high-grade cervical disease: proposal for new guidelines based on data from the Netherlands. J. Low. Genit. Tract Dis. 2014, 18:338-343.
23. Uijterwaal M.H., Verhoef V.M., Snijders P.J., Meijer C.J. Arguments in favor of HPV testing for cervical screening and post-treatment CIN2+ monitoring. Expert Rev. Mol. Diagn. 2014, 14:245-248.
24. Gosvig C.F., Huusom L.D., Andersen K.K., Duun-Henriksen A.K., Frederiksen K., Iftner A., Svare E., Iftner T., Kjaer S.K. Long-term follow-up of the risk for cervical intraepithelial neoplasia grade 2 or worse in HPV-negative women after conization. Int. J. Cancer 2015, 137:2927-2933.
25. Katki H.A., Schiffman M., Castle P.E., Fetterman B., Poitras N.E., Lorey T., Cheung L.C., Raine-Bennett T., Gage J.C., Kinney W.K. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. J. Low. Genit. Tract Dis. 2013, 17(Suppl. 1 (5)):S78-S84.
26. Cubie H.A., Canham M., Moore C., Pedraza J., Graham C., Cuschieri K. Evaluation of commercial PV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H). J. Clin. Pathol. 2014, 67:458-463.
27. Morrell S., Qian L. A whole-population profile of HPV testing as a test of cure for high-grade cervical dysplasia in NSW, Australia. J. Med. Screen. 2014, 21:151-162.
28. Cuzick J., Bergeron C., von Knebel Doeberitz M., Gravitt P., Jeronimo J., Lorincz A.T., JLM Meijer C., Sankaranarayanan R., JF Snijders P., Szarewski A. New technologies and procedures for cervical cancer screening. Vaccine 2012, 30(Suppl. (5)):F107-F116.
29. Söderlund-Strand A., Rymark P., Andersson P., Dillner J., Dillner L. Comparison between the hybrid capture II test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J. Clin. Microbiol. 2005, 43:3260-3266.
30. Rebolj M., Preisler S., Ejegod D.M., Rygaard C., Lynge E., Bonde J. Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening. PLoS One 2014, 9:e86835.
31. Innamaa A., Dudding N., Ellis K., Crossley J., Smith J.H., Tidy J.A., Palmer J.E. High-risk HPV: platforms and test of cure: should specific HPV platforms more suited to screening in a 'test of cure' scenario be recommended?. Cytopathology 2014, [Epub ahead of print]. 10.1111/cyt.12223.
32. Heymans J., Benoy I.H., Poppe W., Depuydt C.E. Type-specific HPV: geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation. Int. J. Cancer 2011, 129:903-909.
33. Jones J., Saleem A., Rai N., Shylasree T.S., Ashman S., Gregory K., Powell N., Tristram A., Fiander A., Hibbitts S. Human papillomavirus genotype testing combined with cytology as a 'test of cure' post treatment: the importance of a persistent viral infection. J. Clin. Virol. 2011, 52:88-92.
34. Ryu A., Nam K., Kwak J., Kim J., Jeon S. Early human papillomavirus testing predicts residual/recurrent disease after LEEP. J. Gynecol. Oncol. 2012, 23:217-225.
35. Venturoli S., Ambretti S., Cricca M., Leo E., Costa S., Musiani M., Zerbini M. Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment. J. Med. Virol. 2008, 80:1434-1440.
36. Söderlund-Strand A., Kjellberg L., Dillner J. Human papillomavirus type-specific persistence and recurrence after treatment for cervical dysplasia. J. Med. Virol. 2014, 86:634-641.
37. Gosvig C.F., Huusom L.D., Andersen K.K., Iftner A., Cederkvist L., Svare E., Iftner T., Kjaer S.K. Persistence and reappearance of high-risk human papillomavirus after conization. Gynecol. Oncol. 2013, 131:661-666.
38. Gök M., Coupé V.M., Berkhof J., Verheijen R.H., Helmerhorst T.J., Hogewoning C.J., Snijders P.J., Meijer C.J. HPV16 and increased risk of recurrence after treatment for CIN. Gynecol. Oncol. 2007, 104:273-275.
39. Cruickshank M.E., Sharp L., Chambers G., Smart L., Murray G. Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia. BJOG 2002, 109:579-581.
40. Thomsen L.T., Frederiksen K., Munk C., Junge J., Iftner T., Kjaer S.K. Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology. Int. J. Cancer 2015, 137:193-203.
41. Arbyn A., Depuydt C., Benoy I., Bogers J., Cuschieri K., Schmitt M., Pawlita M., Geraets D., Herd I., Gheit T., Tommasino M., Poljak M., Bonde J., Quint W. VALGENT: a protocol for clinical validation of human papillomavirus assays. J. Clin. Virol. 2015.
42. Frega A., Sesti F., Lombardi D., Votano S., Sopracordevole F., Catalano A., Milazzo G.N., Lombardo R., Assorgi C., Olivola S., Chiusuri V., Ricciardi E., French D., Moscarini M. Assessment of HPV-mRNA test to predict recurrent disease in patients previously treated for CIN 2/3. J. Clin. Virol. 2014, 60:39-43.
43. Tropé A., Jonassen C.M., Sjøborg K.D., Nygård M., Dahl F.A., Alfsen G.C., Lie A.K. Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia. Gynecol. Oncol. 2011, 123:257-262.
44. Persson M., Brismar Wendel S., Ljungblad L., Johansson B., Weiderpass E., Andersson S. High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia. Oncol. Rep. 2012, 28:346-352.
45. http://www.cancerscreening.nhs.uk/cervical/hpv-triage-test-flowchart-201407.pdf.
46. Costa S., Venturoli S., Origoni M., Preti M., Mariani L., Cristoforoni P., Sandri M.T. Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma. Ecancermedicalscience 2015, 9:528.
47. Costa S., Venturoli S., Negri G., Sideri M., Preti M., Pesaresi M., Falasca A., Barbieri D., Zerbini M., Santini D., Sandri M.T., Ghiringhello B., Caroppo Venturini N., Syrjänen S., Syrjänen K. Factors predicting the outcome of conservatively treated adenocarcinoma in situ of the uterine cervix: an analysis of 166 cases. Gynecol. Oncol. 2012, 124:490-495.
48. Costa S., Negri G., Sideri M., Santini D., Martinelli G., Venturoli S., Pelusi C., Syrjanen S., Syrjanen K., Pelusi G. Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix. Gynecol. Oncol. 2007, 106:170-176.
49. Pathak N., Dodds J., Zamora J., Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ 2014, 349:g5264. 10.1136/bmj.g5264.
50. Arbyn M., Verdoodt F., Snijders P.J., Verhoef V.M., Suonio E., Dillner L., Minozzi S., Bellisario C., Banzi R., Zhao F.H., Hillemanns P., Anttila A. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014, 15:172-183.
51. Taylor S., Wang C., Wright T.C., Denny L., Kuhn L. A comparison of human papillomavirus testing of clinician-collected and self-collected samples during follow-up after screen-and-treat. Int. J. Cancer 2011, 129:879-886.
52. Stanczuk G.A., Currie H., Baxter G., Foster A., Gibson L., Graham C., Cuschieri K. Cobas 4800HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment. J. Clin. Pathol. 2015, 68:567-570.
53. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., Arbyn M., Bosch F.X., Cuzick J., Dillner J., Heideman D.A., Snijders P.J. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 2009, 124:516-520.
54. Arbyn M., Snijders P.J., Meijer C.J., Berkhof J., Cuschieri K., Kocjan B.J., Poljak M. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?. Clin. Microbiol. Infect. 2015, 53:3272-3279.
55. Arbyn M., Anttila A., Jordan J., Ronco G., Schenck U., Segnan N., Wiener H., Herbert A., von Karsa L. European guidelines for quality assurance in cervical cancer screening. Second edition-summary document. Ann. Oncol. 2010, 21:448-458.